TY - JOUR
T1 - Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis
AU - For the International Myositis Assessment
AU - Clinical Studies Group (IMACS) Calcinosis Scientific Interest Group
AU - Chung, Melody P.
AU - Richardson, Carrie
AU - Kirakossian, David
AU - Orandi, Amir B.
AU - Saketkoo, Lesley A.
AU - Rider, Lisa G.
AU - Schiffenbauer, Adam
AU - von Mühlen, Carlos A.
AU - Chung, Lorinda
N1 - Funding Information:
MC receives funding from the Training Program in Adult and Pediatric Rheumatology 5T32AR050942–12. LC receives funding from the Scleroderma Research Foundation . This work was supported in part by the Intramural Research program of the National Institute of Environmental Health Sciences [project ES101074 ].
Publisher Copyright:
© 2020
PY - 2020/6
Y1 - 2020/6
N2 - Dermatomyositis (DM) is a rare idiopathic inflammatory myopathy characterized by muscle weakness and cutaneous manifestations in adults and children. Calcinosis, a complication of DM, is the abnormal deposition of insoluble calcium salts in tissues, including skin, subcutaneous tissue, tendons, fascia, and muscle. Calcinosis is more commonly seen in juvenile DM (JDM), but also develops in adult DM. Although the mechanism of calcinosis remains unclear, several pathogenic hypotheses have been proposed, including intracellular accumulation of calcium secondary to an alteration of the cellular membrane by trauma and inflammation, local vascular ischemia, dysregulation of mechanisms controlling the deposition and solubility of calcium and phosphate, and mitochondrial damage of muscle cells. Identifying calcinosis biomarkers is important for early disease detection and risk assessment, and may lead to novel therapeutic targets for the prevention and treatment of DM-associated calcinosis. In this review, we summarize myositis autoantibodies associated with calcinosis in DM, histopathology and chemical composition of calcinosis, genetic and inflammatory markers that have been studied in adult DM and JDM-associated calcinosis, as well as potential novel biomarkers.
AB - Dermatomyositis (DM) is a rare idiopathic inflammatory myopathy characterized by muscle weakness and cutaneous manifestations in adults and children. Calcinosis, a complication of DM, is the abnormal deposition of insoluble calcium salts in tissues, including skin, subcutaneous tissue, tendons, fascia, and muscle. Calcinosis is more commonly seen in juvenile DM (JDM), but also develops in adult DM. Although the mechanism of calcinosis remains unclear, several pathogenic hypotheses have been proposed, including intracellular accumulation of calcium secondary to an alteration of the cellular membrane by trauma and inflammation, local vascular ischemia, dysregulation of mechanisms controlling the deposition and solubility of calcium and phosphate, and mitochondrial damage of muscle cells. Identifying calcinosis biomarkers is important for early disease detection and risk assessment, and may lead to novel therapeutic targets for the prevention and treatment of DM-associated calcinosis. In this review, we summarize myositis autoantibodies associated with calcinosis in DM, histopathology and chemical composition of calcinosis, genetic and inflammatory markers that have been studied in adult DM and JDM-associated calcinosis, as well as potential novel biomarkers.
KW - Autoantibodies
KW - Calcinosis
KW - Dermatoyositis
UR - http://www.scopus.com/inward/record.url?scp=85083004192&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083004192&partnerID=8YFLogxK
U2 - 10.1016/j.autrev.2020.102533
DO - 10.1016/j.autrev.2020.102533
M3 - Review article
C2 - 32234404
AN - SCOPUS:85083004192
SN - 1568-9972
VL - 19
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
IS - 6
M1 - 102533
ER -